PEGylated recombinant human growth hormone compounds

US12274737B2 · kind B2 · utility

Assignee

• ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S · DK

Inventors

• Harald Rau · Würzburg, DE
• Susanne Kindermann · Liestal, CH
• Torben Leßmann · Neustadt an der Weinstraße, DE
• Grethe Norskov Rasmussen · Farum, DK
• Ulrich Hersel · Heidelberg, DE
• Thomas Wegge · Heidelberg, DE
• Kennett Sprogøe · Rudegård, DK

Key dates

• Filing date: Mar 29, 2021
• Grant date: Apr 15, 2025
• Expiry date: Sep 4, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/61
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.